Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02429232
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
- Conditions
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 89
- Registration Number
- NCT02401880
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪Profil Mainz GmbH & Co. KG, Mainz, Germany
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
- Conditions
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- ikfe-CRO GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT02376075
- Locations
- 🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Rhineland-Palatinate, Germany
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- University at Buffalo
- Target Recruit Count
- 40
- Registration Number
- NCT02372630
- Locations
- 🇺🇸
ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States
Effects of Linagliptin on Endothelial Function
- Conditions
- Interventions
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 49
- Registration Number
- NCT02350478
- Locations
- 🇦🇹
Medical University of Graz, Department for Internal Medicine, Graz, Austria
Effect of Linagliptin on TRL Metabolism
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Ministry of Public Health, Argentina
- Target Recruit Count
- 20
- Registration Number
- NCT02280174
- Locations
- 🇦🇷
National University of Formosa, Formosa, Argentina
Linagliptin as Add on to Basal Insulin in the Elderly
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 302
- Registration Number
- NCT02240680
- Locations
- 🇯🇵
Jiyugaoka Yamada Clinic, Hokkaido, Obihiro, Japan
🇯🇵Yoshida Memorial Hospital, Hokkaido, Sapporo, Japan
🇺🇸East Coast Institute for Research LLC at NE FL Endo & Diabetes, Jacksonville, Florida, United States
Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02220647
Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 95
- Registration Number
- NCT02221414
Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02221401
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.